Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090026 | 0.86 | HPGD (0.44) | TSHRHPGDMEN1ALDH1A1LMNA | |
| SCHEMBL15592253 | 0.86 | TSHR (0.53) | TSHRACE2HPGDKDM4EMEN1 | |
| SCHEMBL25016679 | 0.85 | OPRK1 (0.51) | HPGDKDM4E | |
| SCHEMBL11704496 | 0.83 | PDK1 (0.49) | HPGDKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL8293311 | 0.83 | TSHR (0.50) | TSHREPHX2NR1H4ACE2NR4A2 | |
| SCHEMBL17198001 | 0.82 | TSHR (0.61) | TSHREPHX2NR1H4NR4A2MEN1 | |
| SCHEMBL1355576 | 0.81 | ACE2 (0.45) | TSHRACE2HPGDKDM4EMEN1 | |
| SCHEMBL23346538 | 0.81 | ALDH1A1 (0.46) | TSHRACE2HPGDKDM4EMEN1 | |
| SCHEMBL7772612 | 0.81 | KDM4E (0.52) | ACE2HPGDKDM4EMEN1LMNA | |
| SCHEMBL2538201 | 0.81 | EPHX2 (0.49) | TSHREPHX2ACE2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266867-B2 | Piperidinyl monocarboxylic acids as S1P1 receptor agonists | BIOPROJET (FR) | 2016-02-23 | — | — | US | disclosed |
| EP-2697219-B1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2015-03-04 | — | — | EP | disclosed |
| EP-2697219-B1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2015-03-04 | — | — | EP | disclosed |
| US-20140099316-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2014-04-10 | — | — | US | disclosed |
| EP-2697219-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | Bioprojet (FR) | 2014-02-19 | — | — | EP | disclosed |
| CN-101663297-B | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-103012390-A | Indole derivatives as S1P1 receptor | GLAXO GROUP LTD | 2013-04-03 | — | — | CN | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| CN-101663297-A | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | GLAXO GROUP LTD | 2010-03-03 | — | — | CN | disclosed |
| EP-2137181-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| CN-101611033-A | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD (GB) | 2009-12-23 | — | — | CN | disclosed |
| EP-2091949-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1873153-A1 | HETEROCYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | TPMT, AZI2, IDO1 | TSHR 1752/4885EPHX2 2888/4885NR1H4 2032/4885 |
| US-20140099316-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | TSHR 802/4885EPHX2 3042/4885NR1H4 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.